CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...

The German automaker has seen sales stall, quality concerns rise and its electric vehicle initiatives fail, leading the board ...

BBVA SA is changing the way it manages its balance sheet as it taps into increased demand for deals that transfer risk out of ...